Bio-Matrix Scientific Group's Regen BioPharma subsidiary will use Cook General Biotechnology as its CMO to make clinical supplies of HemaXellerate I. HemaXellerate I is a personalized stem cell treatment that utilizes fat derived cells to inhibit the biological processes responsible for aplastic anemia. The initial batches will be utilized for completing preclinical experiments requested by the FDA for a clinical trial using HemaXellerate I as a therapeutic for treatment resistant aplastic anemia.
"We are excited to work with the team at Regen BioPharma in producing clinical grade HemaXellerate I, initially for preclinical studies, and subsequently for the clinical trial itself," said Erik J. Woods, Ph.D., chief executive officer of Cook General Biotechnology.
Cook General Bio To Make HemaXellerate I
By Gil Roth
Published November 1, 2013
blog comments powered by Disqus